China Medical System Holdings Limited (0867.HK) HKSE

13.30

+0.17(+1.29%)

Updated at October 20 10:12AM

Currency In HKD

China Medical System Holdings Limited

Address

Island Place Tower

North Point,

Hong Kong

Phone

852 2369 7678

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

6141

First IPO Date

September 28, 2010

Key Executives

NameTitlePayYear Born
Mr. Kong LamFounder, Chairman, Chief Executive Officer & President6.7M1965
Ms. Yanling ChenChief Financial Officer, Vice President & Executive Director5.29M1970
Mr. Hongbing ChenNon-Executive Director5.62M1967
Mr. James Patrick StearnsChief Investment Officer of Europe & America01979
Dr. Huaizheng Peng M.D., Ph.D.Chief Business Officer01962
Mr. Fei JiangChief Investment Officer of Greater China01977
Mr. Lieyi MaGeneral Manager of the Operations & Management Center of the Group01970
Ms. Sanyan WuDirector of Legal Department & Company Secretary01983

Description

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.